Possible involvement of histone acetylation in the development of emotional resistance to stress stimuli in mice

Behavioural Brain Research

Volumn 235, Issue 2, 2012, Pages 318-325

  Miyagawa, K ^a   Tsuji, M ^a   Takeda, H ^a  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Emotional stress resistance; Epigenetics; Histone acetylation; Histone deacetylase; Serotonin 1A receptor; Trichostatin A

Indexed keywords

DIAZEPAM; FLESINOXAN; HISTONE DEACETYLASE; HISTONE H3; HISTONE H4; SEROTONIN 1A RECEPTOR; TRICHOSTATIN A;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; EMOTION; EMOTIONAL STRESS; ENZYME INHIBITION; EPIGENETICS; GENE CONTROL; HIPPOCAMPUS; HISTONE ACETYLATION; HISTONE MODIFICATION; IMMOBILIZATION STRESS; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLATION; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; DIAZEPAM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EMOTIONS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HYDROXAMIC ACIDS; MALE; MICE; MICE, INBRED ICR; PIPERAZINES; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 84865567568     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.08.010     Document Type: Article

References (42)

1. Murphy D. Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems. Neuropsychopharmacology 1990, 3(5-6):457-471. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=2078279.
2. Cowen P. Serotonin receptor subtypes: implications for psychopharmacology. British Journal of Psychiatry 1991, (Suppl. 12):7-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=1840764.
3. Martin G., Humphrey P. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 1994, 33(3-4):261-273. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=7984266.
4. Artigas F., Romero L., de Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neurosciences 1996, 19(9):378-383. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=8873352.
5. Barrett J., Vanover K. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology 1993, 112(1):1-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=7870996.
6. Grof P., Joffe R., Kennedy S., Persad E., Syrotiuk J., Bradford D. An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. International Clinical Psychopharmacology 1993, 8(3):167-172. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=8263314.
7. Murphy D., Lesch K., Aulakh C., Pigott T. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacological Reviews 1991, 43(4):527-552. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=1775507.
8. Pitchot W., Ansseau M., Gonzalez Moreno A., Lembreghts M., Hansenne M., Wauthy J., et al. The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior. Pharmacopsychiatry 1995, 28(Suppl. 2):91-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=8614706.
9. Takeda H., Tsuji M., Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. European Journal of Pharmacology 1998, 350(1):21-29. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=9683010.
10. Tsuji M., Takeda H., Matsumiya T. Different effects of 5-HT1A receptor agonists and benzodiazepine anxiolytics on the emotional state of naive and stressed mice: a study using the hole-board test. Psychopharmacology 2000, 152(2):157-166. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=11057519.
11. Meltzer H., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behavioural Brain Research 2008, 195(1):98-102. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=18707769.
12. Ohno Y. New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders. Central Nervous System Agents in Medicinal Chemistry 2010, 10(2):148-157. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=20518729.
13. Shimizu S., Tatara A., Imaki J., Ohno Y. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34(6):877-881. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=20398719.
14. Blatt G., Fitzgerald C., Guptill J., Booker A., Kemper T., Bauman M. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. Journal of Autism and Developmental Disorders 2001, 31(6):537-543. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=11814263.
15. Janusonis S., Anderson G., Shifrovich I., Rakic P. Ontogeny of brain and blood serotonin levels in 5-HT receptor knockout mice: potential relevance to the neurobiology of autism. Journal of Neurochemistry 2006, 99(3):1019-1031. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=16981893.
16. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine 2003, 349(21):2042-2054. http://www.ncbi.nlm.nih.gov/pubmed/14627790.
17. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403(6765):41-45. http://www.ncbi.nlm.nih.gov/pubmed/10638745.
18. Ng H.H., Bird A. DNA methylation and chromatin modification. Current Opinion in Genetics and Development 1999, 9(2):158-163. http://www.ncbi.nlm.nih.gov/pubmed/10322130.
19. Mill J., Petronis A. Molecular studies of major depressive disorder: the epigenetic perspective. Molecular Psychiatry 2007, 12(9):799-814. http://www.ncbi.nlm.nih.gov/pubmed/17420765.
20. Petronis A. Epigenetics and bipolar disorder: new opportunities and challenges. American Journal of Medical Genetics Part C - Seminars in Medical Genetics 2003, 123C(1):65-75. http://www.ncbi.nlm.nih.gov/pubmed/14601038.
21. Poulter M.O., Du L., Weaver I.C., Palkovits M., Faludi G., Merali Z., et al. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biological Psychiatry 2008, 64(8):645-652. http://www.ncbi.nlm.nih.gov/pubmed/18639864.
22. McGowan P.O., Sasaki A., Huang T.C., Unterberger A., Suderman M., Ernst C., et al. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS ONE 2008, 3(5):e2085. http://www.ncbi.nlm.nih.gov/pubmed/18461137.
23. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonté B., Szyf M., et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neuroscience 2009, 12(3):342-348. http://www.ncbi.nlm.nih.gov/pubmed/19234457.
24. Kriaucionis S., Bird A. DNA methylation and Rett syndrome. Human Molecular Genetics 2003, 12(2):R221-R227. http://www.ncbi.nlm.nih.gov/pubmed/12928486.
25. Crespi B. Genomic imprinting in the development and evolution of psychotic spectrum conditions. Biological Reviews of the Cambridge Philosophical Society 2008, 83(4):441-493. http://www.ncbi.nlm.nih.gov/pubmed/18783362.
26. Schanen N.C. Epigenetics of autism spectrum disorders. Human Molecular Genetics 2006, 15(2):R138-R150. http://www.ncbi.nlm.nih.gov/pubmed/16987877.
27. Kubota T., Miyake K., Hirasawa T., Nagai K., Koide T. Novel etiological and therapeutic strategies for neurodiseases: epigenetic understanding of gene-environment interactions. Journal of Pharmacological Sciences 2010, 113(1):3-8. http://www.ncbi.nlm.nih.gov/pubmed/20424390.
28. Narayan P., Dragunow M. Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology 2010, 159(2):285-303. http://www.ncbi.nlm.nih.gov/pubmed/20015091.
29. Felsenfeld G., Groudine M. Controlling the double helix. Nature 2003, 421(6921):448-453. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=12540921.
30. Jenuwein T., Allis C. Translating the histone code. Science 2001, 293(5532):1074-1080. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fcmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=11498575.
31. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311(5762):864-868. http://www.ncbi.nlm.nih.gov/pubmed/16469931.
32. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience 2006, 9(4):519-525. http://www.ncbi.nlm.nih.gov/pubmed/16501568.
33. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., et al. Epigenetic programming by maternal behavior. Nature Neuroscience 2004, 7(8):847-854. http://www.ncbi.nlm.nih.gov/pubmed/15220929.
34. Tsuji M., Miyagawa K., Takeuchi T., Hiroshi T. DNA microarray analysis of gene expression profile in the hippocampus of mice with resistance to stress stimuli. Journal of Pharmacological Sciences 2008, 106(Suppl. 2):141-141.
35. Stone E.A., Trullas R., Platt J.E. The effect of acute and chronic administration of desmethylimipramine on responses to stress in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1984, 8(4-6):587-592. http://www.ncbi.nlm.nih.gov/pubmed/6597939.
36. Rodríguez Echandía E.L., Broitman S.T., Fóscolo M.R. Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats. Pharmacology Biochemistry and Behavior 1987, 26(2):207-210. http://www.ncbi.nlm.nih.gov/pubmed/3575344.
37. Tsuji M., Takeda H., Matsumiya T. Protective effects of 5-HT1A receptor agonists against emotional changes produced by stress stimuli are related to their neuroendocrine effects. British Journal of Pharmacology 2001, 134(3):585-595. http://www.ncbi.nlm.nih.gov/pubmed/11588113.
38. Ahlenius S., Larsson K., Wijkström A. Behavioral and biochemical effects of the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT in the rat. European Journal of Pharmacology 1991, 200(2-3):259-266. http://www.ncbi.nlm.nih.gov/pubmed/1838333.
39. Rodgers R.J., Cole J.C., Davies A. Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacology Biochemistry and Behavior 1994, 48(4):959-963. http://www.ncbi.nlm.nih.gov/pubmed/7972301.
40. Dong E., Guidotti A., Grayson D.R., Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(11):4676-4681. http://www.ncbi.nlm.nih.gov/pubmed/17360583.
41. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genetics 2003, 33(Suppl.):245-254. http://www.ncbi.nlm.nih.gov/pubmed/12610534.
42. Tremolizzo L., Doueiri M.S., Dong E., Grayson D.R., Davis J., Pinna G., et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biological Psychiatry 2005, 57(5):500-509. http://www.ncbi.nlm.nih.gov/pubmed/15737665.